Logo

ARDT

Ardent Health Partners, LLC

ARDT

Ardent Health Partners, LLC • NYSE
$8.78 ▼ -2.98% (-0.27)
Market Cap $1.26 B
52w High $17.34
52w Low $8.28
Dividend Yield 0%
P/E 5.93
Volume 281.68K
Outstanding Shares 143.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.577B ▼ $645.456M ▼ $-23.478M ▼ -1.489% ▼ $-0.17 ▼ $55.614M ▼
Q2-2025 $1.645B ▲ $1.237B ▲ $72.95M ▲ 4.434% ▲ $0.52 ▲ $176.03M ▲
Q1-2025 $1.497B ▼ $1.171B ▲ $41.383M ▼ 2.764% ▼ $0.3 ▼ $124.575M ▼
Q4-2024 $1.606B ▲ $615.529M ▼ $114.204M ▲ 7.11% ▲ $0.8 ▲ $195.426M ▲
Q3-2024 $1.45B $1.128B $26.322M 1.816% $0.19 $108.467M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $609.441M ▲ $5.154B ▲ $3.523B ▲ $1.238B ▼
Q2-2025 $540.629M ▲ $5.027B ▲ $3.381B ▲ $1.255B ▲
Q1-2025 $495.044M ▼ $4.911B ▼ $3.347B ▼ $1.175B ▲
Q4-2024 $556.785M ▼ $4.956B ▲ $3.434B ▲ $1.131B ▲
Q3-2024 $563.142M $4.8B $3.413B $1.006B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-23.478M ▼ $151.799M ▲ $-58.632M ▼ $-24.355M ▲ $68.812M ▲ $92.995M ▲
Q2-2025 $95.701M ▲ $117.49M ▲ $-46.247M ▼ $-25.658M ▼ $45.585M ▲ $71.293M ▲
Q1-2025 $58.965M ▼ $-24.787M ▼ $-23.122M ▲ $-13.832M ▲ $-61.741M ▼ $-47.695M ▼
Q4-2024 $114.204M ▲ $119.569M ▲ $-105.444M ▼ $-20.482M ▼ $-6.357M ▼ $38.295M ▼
Q3-2024 $26.322M $92.152M $-44.509M $180.961M $228.604M $48.683M

Revenue by Products

Product Q1-2025Q2-2025
Reportable Segment
Reportable Segment
 $1.50Bn ▲$1.65Bn ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the last few years, showing a business that is expanding at a healthy, but not explosive, pace. Profitability has improved, with operating and net income both trending higher and moving in the right direction. Margins look stronger than they were a few years ago, suggesting better cost control, improved payer mix, or more efficient operations. One year shows especially strong gross profitability, which may reflect mix shifts or one‑off effects, so it may not be fully repeatable. Overall, the income statement points to a company that has moved from simply stable to meaningfully profitable, though earnings are still modest relative to the size of the business and remain sensitive to labor costs and reimbursement pressure.

Balance Sheet

Balance Sheet The balance sheet shows a typical hospital operator profile: substantial fixed assets, notable debt, and a growing equity base. Total assets have inched up over time, while debt has started to come down slightly, which is a positive sign for financial risk. Equity has increased meaningfully, reflecting retained earnings and a stronger capital position. Cash on hand has improved, giving the company a better liquidity cushion, though not so large that it can ignore capital needs or shocks. Overall leverage remains an important consideration, but the direction of change is favorable, with gradual de‑risking rather than aggressive balance sheet expansion.

Cash Flow

Cash Flow Cash generation has improved from a weak patch a few years ago to consistently positive operating cash flow more recently. Free cash flow has turned from negative to positive, even after ongoing investments in facilities and equipment. Capital spending appears steady and disciplined, suggesting a focus on maintaining and selectively expanding capacity rather than large, risky build‑outs. The pattern indicates a business increasingly able to fund its own growth and debt service from internal cash, but with limited room for major missteps or big cyclical downturns. Working capital and collections performance will remain key watchpoints in such a cash‑intensive, reimbursement‑driven business.

Competitive Edge

Competitive Edge Ardent competes in a tough space but has carved out a distinct position through joint ventures with major academic and not‑for‑profit health systems. This partner‑driven model lets it blend local community hospital operations expertise with the brand, reputation, and clinical depth of large systems, creating a barrier that is not easy to copy. Its focus on growing, mid‑sized urban markets means it often faces less head‑to‑head competition from the very largest national chains, while still benefiting from attractive demographics. The expansion into ambulatory and urgent care sites deepens its presence in these communities and helps pull more patients into its network. That said, it still faces intense pressure from other regional systems, physician groups, and non‑traditional care providers, as well as ongoing wage and reimbursement challenges.

Innovation and R&D

Innovation and R&D Innovation is a clear strategic priority, centered on artificial intelligence, digital tools, and care outside the hospital walls. The in‑house innovation studio and multiple AI partnerships aim to streamline nursing workflows, monitor patients with wearables, optimize operating rooms, and improve overall hospital efficiency. The company is also investing in its “digital front door” and virtual care capabilities, which, if executed well, can improve patient access and stickiness. Parallel expansion into urgent care and ambulatory surgery centers creates a more consumer‑friendly, connected care network that feeds volume into its hospitals and specialists. The opportunity is significant, but success depends on real operational gains from these technologies, smooth integration across sites, and careful management of data, regulatory, and change‑management risks.

Summary

Overall, Ardent looks like a maturing healthcare platform: revenue is growing steadily, profitability and cash flow have improved, and the balance sheet is slowly strengthening. The business remains capital‑intensive and levered, but trends in equity, cash, and debt are moving in a healthier direction. Competitively, the joint‑venture model with leading health systems and the focus on mid‑sized urban markets give it a differentiated, partnership‑driven footprint. Its push into AI, digital tools, and ambulatory care suggests a management team leaning into industry change rather than resisting it. Going forward, the company’s trajectory will hinge on maintaining margin improvements, managing leverage prudently, and turning its innovation and ambulatory strategies into durable, day‑to‑day operational advantages in a highly regulated and cost‑pressured environment.

NEWS

November 28, 2025 · 8:18 AM UTC

ARDT INVESTMENT: Ardent Health, Inc. Investors with Losses are Reminded to Contact BFA Law about its Ongoing Securities Class Action Investigation

Read more

November 27, 2025 · 1:23 PM UTC

Ardent Health (ARDT) Investor Alert: Hagens Berman Investigating Accounting Estimate Change and $97M Reserve Issue Driving 33% Plunge

Read more

November 26, 2025 · 9:50 AM UTC

ARDT Investors Have Opportunity to Join Ardent Health, Inc. Fraud Investigation with the Schall Law Firm

Read more

November 26, 2025 · 8:50 AM UTC

Ardent Health (ARDT) Faces Investor Scrutiny Amid Problems Estimating Collection of Accounts Receivable, Disclosure Drives Stock Down 33% -- Hagens Berman

Read more

November 25, 2025 · 9:47 AM UTC

Ardent Health, Inc. Investigated by the Portnoy Law Firm

Read more